Cargando…
Relationship between clinical remission of perianal fistulas in Crohn’s disease and serum adalimumab concentrations: A multi-center cross-sectional study
BACKGROUND: Crohn’s disease (CD) is complicated by perianal fistulas in approximately 20% of patients. Achieving permanent fistula closure remains a challenge for physicians. An association between serum anti-tumor necrosis factor-α concentrations and clinical outcomes in patients with CD has been d...
Autores principales: | Sirmai, Laura, Pelletier, Anne-Laure, Gault, Nathalie, Zallot, Camille, Bouguen, Guillaume, Bouchard, Dominique, Roland Nicaise, Pascale, Peyneau, Marine, Sironneau, Sandrine, Bittencourt, Marcelo De Carvalho, Petitcollin, Antoine, Fernandez, Pedro, Roblin, Xavier, Siproudhis, Laurent, Abramowitz, Laurent |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8908286/ https://www.ncbi.nlm.nih.gov/pubmed/35317057 http://dx.doi.org/10.3748/wjg.v28.i9.961 |
Ejemplares similares
-
Adalimumab or infliximab: which is better for perianal fistula in Crohn's disease?
por: Im, Jong Pil
Publicado: (2017) -
Elaboration and validation of Crohn’s disease anoperineal lesions consensual definitions
por: Horaist, Clémence, et al.
Publicado: (2017) -
Efficacy of ustekinumab, vedolizumab, or a second anti-TNF agent after the failure of a first anti-TNF agent in patients with Crohn’s disease: a multicentre retrospective study
por: Cassandra, Rayer, et al.
Publicado: (2022) -
Correction: Efficacy of ustekinumab, vedolizumab, or a second anti-TNF agent after the failure of a first anti-TNF agent in patients with Crohn’s disease: a multicentre retrospective study
por: Rayer, Cassandra, et al.
Publicado: (2023) -
Higher infliximab and adalimumab trough levels are associated with fistula healing in patients with fistulising perianal Crohn’s disease
por: Gu, Bonita, et al.
Publicado: (2022)